title: Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.
abstract: We have examined the humoral and cellular responses of SLE patients to peptides based on the complementarity-determining regions (CDR) of a monoclonal anti-DNA antibody with a major idiotype- 16/6 Id, in comparison to their responses to the whole 16/6 Id-bearing antibody. Sera of 63% of the SLE patients had antibodies that bound the 16/6 Id, 80% had antibodies to one of the CDR-based peptides, and 40% of the patients reacted with both CDRs. Sera of only a few controls reacted with either the 16/6 Id (6%) or the CDR based peptides (4%) (P < 0.01). Peripheral blood lymphocytes (PBL) of 39% of the patients proliferated in response to the 16/6 Id or to one of the CDR-based peptides (37%), while in the control group the proliferation rates were 66% to the 16/6 Id and 59% to one of the CDR-based peptides (P < 0.05). The correlation between (both) the humoral and cellular immune responses to the CDR-based peptides and to the 16/6 Id suggests the relevance of these peptides to the 16/6 Id and provides additional information on the pathogenic moiety of the latter antibody.
authors.affiliation: Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.
authors.forename: M
authors.initials: M
authors.lastname: Dayan
authors.forename: R
authors.initials: R
authors.lastname: Segal
authors.forename: Z
authors.initials: Z
authors.lastname: Sthoeger
authors.forename: A
authors.initials: A
authors.lastname: Waisman
authors.forename: N
authors.initials: N
authors.lastname: Brosh
authors.forename: O
authors.initials: O
authors.lastname: Elkayam
authors.forename: E
authors.initials: E
authors.lastname: Eilat
authors.forename: M
authors.initials: M
authors.lastname: Fridkin
authors.forename: E
authors.initials: E
authors.lastname: Mozes
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D000974:Antibodies, Antinuclear / Q000235:genetics*; D000911:Antibodies, Monoclonal / Q000235:genetics*; D016022:Case-Control Studies; D022801:Complementarity Determining Regions / Q000235:genetics*; D006801:Humans; D007111:Immunity, Cellular; D007130:Immunoglobulin Idiotypes / Q000235:genetics; D066298:In Vitro Techniques; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008969:Molecular Sequence Data; D010455:Peptides / Q000235:genetics* / Q000276:immunology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D022801:Complementarity Determining Regions; D007130:Immunoglobulin Idiotypes; D010455:Peptides